Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
-
Metastatic malignant melanoma belongs to a group of cancers with high mortality. In recent years, advances in our knowledge of the pathogenesis of melanoma and the discovery of new drugs has resulted in significant progress in the treatment of metastatic malignant melanoma patients. The development of resistance to these drugs, however, remains a challenge. One way how to avoid resistance, or at least delay it, is to administer combination therapy. ⋯ This case study demonstrates that combination therapy with a BRAF and a MEK inhibitor can be used to successfully treat metastatic malignant melanoma patients and suggests they should be employed in therapeutic algorithms for patients with metastatic malignant melanoma and BRAF gene mutations.
-
Targeted therapy of lung cancer has brought significant improvement in prognosis for a lot of patients with EGFR-sensitive mutations and ALK translocations. Other clinical studies have shown ROS1 translocation as another potential target. Our case report brings probably the first successful use of crizotininib in a patient with ROS1 translocation in the Czech Republic. ⋯ During the control PET/ CT scans, partial regression of the disease was observed. ROS1 translocation becomes another promising target for our patients. Therefore, in our opinion, serious discussion about its inclusion among the basic genetic testing in lung adenocarcinomas should occur.